![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1722760
»ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀå º¸°í¼ : ¹æ¹ý, ¿ëµµ, Áö¿ªº°(2025-2033³â)Separation Systems for Commercial Biotechnology Market Report by Methods (Modern Methods, Conventional Methods), Application (Pharmaceutical, Food and Cosmetics, Agriculture, and Others), and Region 2025-2033 |
¼¼°è »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2024³â 282¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 447¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 4.98%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù.
»ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛÀº »ýÈÇÐ ¹°Áú, Áø´Ü ½Ã¾à, ¹ÙÀÌ¿À ÀǾàǰÀ» Æ÷ÇÔÇÑ º¹ÀâÇÑ È¥ÇÕ¹°À̳ª ¿ë¾×¿¡¼ »ý¹°ÇÐÀû Á¦Ç°À» Á¤Á¦ ¹× ºÐ¸®ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¼Ö·ç¼ÇÀ» ¸»ÇÕ´Ï´Ù. ºÐ¸®´Â Á¦Ç°ÀÇ Á¤ÀüÇÏ, ¹Ðµµ, ÇüÅÂ, ±Ø¼º, ¿ëÇØµµ, È®»ê¼º, Èֹ߼º¿¡ µû¶ó ÀÌ·ç¾îÁý´Ï´Ù. ºÐ¸®¿¡´Â Å©·Î¸¶Åä±×·¡ÇÁ, ¸âºê·¹ÀÎ, ÇÊÅÍ, ¿ø½ÉºÐ¸®±â, ¹ÙÀÌ¿ÀĨ, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ µî ´Ù¾çÇÑ ±â±â ¹× ÀåÄ¡°¡ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ¼öÁöÀÇ »ý»ê¼ºÀ» Çâ»ó½Ã۰í, ȸ¼öÀ²À» ³ôÀ̸ç, Æó±â¹° ¹ß»ý°ú ¼¼Ã´¼ö »ç¿ëÀ» ÃÖ¼ÒÈÇÕ´Ï´Ù. ±× °á°ú, ºÐ¸® ½Ã½ºÅÛÀº Á¦¾à, ½ÄÀ½·á, ÈÀåǰ, ³ó¾÷ µî ´Ù¾çÇÑ »ê¾÷¿¡¼ Æø³Ð°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
¼¼°è Á¦¾à »ê¾÷ÀÇ °ý¸ñÇÒ¸¸ÇÑ ¼ºÀåÀº ½ÃÀå Àü¸ÁÀ» ¹à°Ô ÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¸¸¼º ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÂÃãÇü ÀǾàǰ, ¹ÙÀÌ¿À ÀǾàǰ ¹× ¼¼Æ÷ ±â¹Ý Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â »ó¾÷¿ë »ý¸í °øÇÐ¿ë ºÐ¸® ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÃ¶ó½ºÆ½ ¹× ÈÇÐÁ¦Ç°ÀÇ »ó¾÷Àû »ý»ê¿¡ Àڱ⠺и®±â°¡ ³Î¸® äÅõǰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °£¼ÒÈµÈ ÀýÂ÷·Î »ý¹°ÇÐÀû À§Çè ¿ä¼Ò¸¦ Á¦Ç°º°·Î Á¦°ÅÇÏ´Â Çõ½ÅÀûÀÎ ¾÷½ºÆ®¸² ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼úÀÇ °³¹ß µî ´Ù¾çÇÑ ±â¼ú ¹ßÀüÀÌ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¿¬±¸¼Ò ¹× ¿¬±¸±â°üµéµµ °í°¨µµ ¹× °íºÐÀÚ ºÐ¸®¸¦ À§ÇØ »õ·Î¿î °í¼º´É °¡½º Å©·Î¸¶Åä±×·¡ÇÁ, ÃÊÀÓ°è À¯Ã¼ Å©·Î¸¶Åä±×·¡ÇÁ, ¿ø½ÉºÐ¸®, Àü±â¿µµ¿ ÀåÄ¡ µîÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ, ƯÈ÷ ½ÅÈï °æÁ¦±¹ÀÇ ÇコÄɾî ÀÎÇÁ¶ó °³¼±°ú »ý¸í°øÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
The global separation systems for commercial biotechnology market size reached USD 28.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 44.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.98% during 2025-2033.
The separation systems for commercial biotechnology refer to the solutions used for the purification and separation of biological products from complex mixtures and solutions, including biochemicals, diagnostic reagents and biopharmaceuticals. The separation is based on the electrostatic charge, density, shape, polarity, solubility, diffusivity and volatility of the product. It involves the use of various equipment and devices, such as chromatographs, membranes, filters, centrifuges, biochips and microarrays. These solutions offer improved resin productivity, higher recovery and minimal waste generation and wash water usage. As a result, separation systems find extensive applications across various industries, including pharmaceutical, food and beverage, cosmetic and agriculture.
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. With the increasing prevalence of chronic medical ailments, there is a rising demand for personalized drugs, biopharmaceuticals and cell-based therapies, which is impacting the demand for separation systems for commercial biotechnology. Moreover, the widespread adoption of magnetic separators for the commercial production of plastics and chemicals is providing a thrust to the market growth. Additionally, various technological advancements, such as the development of innovative upstream bioprocessing technologies that facilitate in the elimination of biohazardous by-products using simplified procedures, are acting as growth-inducing factors. Biotechnological institutes and research organizations are also using novel high-performance gas and supercritical fluid chromatography, centrifugation and electrophoresis equipment for the separation of sensitive and large molecules. Other factors, including improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) in the field of biotechnology, are anticipated to drive the market toward growth.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Hitachi Ltd., Merck KGaA, Pall Corporation (Danaher Corporation), PerkinElmer Inc., Qiagen N.V, Repligen Corporation, Sartorius AG, Shimadzu Corporation and Thermo Fisher Scientific.